Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
- 19 September 2023
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (1) , 23-31
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blastsOncotarget, 2016
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyJournal of Clinical Oncology, 2016
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeJournal of Clinical Oncology, 2016
- Chronic myeloid leukemia: Second‐line drugs of choiceAmerican Journal of Hematology, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphomaBlood, 2014
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agentsLeukemia, 2013
- Anti-CD20 Therapy for Chronic Lymphocytic Leukemia-associated Autoimmune DiseasesLeukemia & Lymphoma, 2003
- Rituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood, 2001
- Regulation of surface and intracellular expression of CTLA4 on mouse T cellsThe Journal of Immunology, 1996